APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Human Insulin

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Insulin Market Outlook and Growth Opportunities 2026

Report ID 173999900420 December 2025190 pages

Choose your research edition.

Industry ResearchHuman Insulin Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Insulin Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Human Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Insulin Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Insulin Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Human Insulin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Insulin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Insulin market include Sanofi, ELI Lilly, B. Braun, Ypsomed, Wockhardt, NOVO Nordisk, Julphar, Biodel and Biocon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Insulin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Insulin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Insulin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Insulin market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Insulin Segment by Company

Sanofi

ELI Lilly

B. Braun

Ypsomed

Wockhardt

NOVO Nordisk

Julphar

Biodel

Biocon

Becton, Dickinson

Human Insulin Segment by Type

Insulin Analogs and Biosimilars

Human Insulin Biologics

Human Insulin Segment by Application

Short Acting

Pre-Mix Insulin

Long Acting

Intermediate Acting

Human Insulin Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Human Insulin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human Insulin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Insulin significant trends, drivers, influence factors in global and regions.

6. To analyze Human Insulin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Insulin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Insulin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Insulin industry.

Chapter 3: Detailed analysis of Human Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human Insulin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Insulin Industry Trends Table 2. Human Insulin Industry Drivers Table 3. Human Insulin Industry Opportunities and Challenges Table 4. Human Insulin Industry Restraints Table 5. Global Human Insulin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Insulin Revenue Share by Company (2021-2026) Table 7. Global Human Insulin Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Human Insulin Sales Volume Share by Company (2021-2026) Table 9. Global Human Insulin Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Human Insulin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human Insulin Key Company Manufacturing Base & Headquarters Table 12. Global Human Insulin Company, Product Type & Application Table 13. Global Human Insulin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Insulin Analogs and Biosimilars Table 18. Significant Companies of Human Insulin Biologics Table 19. Global Human Insulin Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Human Insulin Sales Volume by Type (2021-2026) & (W Units) Table 21. Global Human Insulin Sales Volume by Type (2027-2032) & (W Units) Table 22. Global Human Insulin Sales Volume Share by Type (2021-2026) Table 23. Global Human Insulin Sales Volume Share by Type (2027-2032) Table 24. Global Human Insulin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Human Insulin Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Human Insulin Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Human Insulin Sales Value Share by Type (2021-2026) Table 28. Global Human Insulin Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Short Acting Table 30. Significant Companies of Pre-Mix Insulin Table 31. Significant Companies of Long Acting Table 32. Significant Companies of Intermediate Acting Table 33. Global Human Insulin Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 34. Global Human Insulin Sales Volume by Application (2021-2026) & (W Units) Table 35. Global Human Insulin Sales Volume by Application (2027-2032) & (W Units) Table 36. Global Human Insulin Sales Volume Share by Application (2021-2026) Table 37. Global Human Insulin Sales Volume Share by Application (2027-2032) Table 38. Global Human Insulin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Human Insulin Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Human Insulin Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Human Insulin Sales Value Share by Application (2021-2026) Table 42. Global Human Insulin Sales Value Share by Application (2027-2032) Table 43. Global Human Insulin Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 44. Global Human Insulin Sales by Region (2021-2026) & (W Units) Table 45. Global Human Insulin Sales Market Share by Region (2021-2026) Table 46. Global Human Insulin Sales by Region (2027-2032) & (W Units) Table 47. Global Human Insulin Sales Market Share by Region (2027-2032) Table 48. Global Human Insulin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Human Insulin Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Human Insulin Sales Value Share by Region (2021-2026) Table 51. Global Human Insulin Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Human Insulin Sales Value Share by Region (2027-2032) Table 53. Global Human Insulin Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Human Insulin Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Human Insulin Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. Global Human Insulin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Human Insulin Sales by Country (2021-2026) & (W Units) Table 58. Global Human Insulin Sales Market Share by Country (2021-2026) Table 59. Global Human Insulin Sales by Country (2027-2032) & (W Units) Table 60. Global Human Insulin Sales Market Share by Country (2027-2032) Table 61. Global Human Insulin Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Human Insulin Sales Value Market Share by Country (2021-2026) Table 63. Global Human Insulin Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Human Insulin Sales Value Market Share by Country (2027-2032) Table 65. Sanofi Company Information Table 66. Sanofi Business Overview Table 67. Sanofi Human Insulin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Sanofi Human Insulin Product Portfolio Table 69. Sanofi Recent Development Table 70. ELI Lilly Company Information Table 71. ELI Lilly Business Overview Table 72. ELI Lilly Human Insulin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. ELI Lilly Human Insulin Product Portfolio Table 74. ELI Lilly Recent Development Table 75. B. Braun Company Information Table 76. B. Braun Business Overview Table 77. B. Braun Human Insulin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. B. Braun Human Insulin Product Portfolio Table 79. B. Braun Recent Development Table 80. Ypsomed Company Information Table 81. Ypsomed Business Overview Table 82. Ypsomed Human Insulin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Ypsomed Human Insulin Product Portfolio Table 84. Ypsomed Recent Development Table 85. Wockhardt Company Information Table 86. Wockhardt Business Overview Table 87. Wockhardt Human Insulin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Wockhardt Human Insulin Product Portfolio Table 89. Wockhardt Recent Development Table 90. NOVO Nordisk Company Information Table 91. NOVO Nordisk Business Overview Table 92. NOVO Nordisk Human Insulin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. NOVO Nordisk Human Insulin Product Portfolio Table 94. NOVO Nordisk Recent Development Table 95. Julphar Company Information Table 96. Julphar Business Overview Table 97. Julphar Human Insulin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Julphar Human Insulin Product Portfolio Table 99. Julphar Recent Development Table 100. Biodel Company Information Table 101. Biodel Business Overview Table 102. Biodel Human Insulin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Biodel Human Insulin Product Portfolio Table 104. Biodel Recent Development Table 105. Biocon Company Information Table 106. Biocon Business Overview Table 107. Biocon Human Insulin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Biocon Human Insulin Product Portfolio Table 109. Biocon Recent Development Table 110. Becton, Dickinson Company Information Table 111. Becton, Dickinson Business Overview Table 112. Becton, Dickinson Human Insulin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Becton, Dickinson Human Insulin Product Portfolio Table 114. Becton, Dickinson Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Human Insulin Distributors List Table 118. Human Insulin Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Human Insulin Product Image Figure 2. Global Human Insulin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Insulin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human Insulin Sales (2021-2032) & (W Units) Figure 5. Global Human Insulin Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Human Insulin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Insulin Analogs and Biosimilars Image Figure 10. Human Insulin Biologics Image Figure 11. Global Human Insulin Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Human Insulin Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Human Insulin Sales Volume Share by Type (2021-2032) Figure 14. Global Human Insulin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Human Insulin Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Human Insulin Sales Value Share by Type (2021-2032) Figure 17. Short Acting Image Figure 18. Pre-Mix Insulin Image Figure 19. Long Acting Image Figure 20. Intermediate Acting Image Figure 21. Global Human Insulin Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 22. Global Human Insulin Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Human Insulin Sales Volume Share by Application (2021-2032) Figure 24. Global Human Insulin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Human Insulin Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Human Insulin Sales Value Share by Application (2021-2032) Figure 27. Global Human Insulin Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 28. Global Human Insulin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Human Insulin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Human Insulin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Human Insulin Sales Value (2021-2032) & (US$ Million) Figure 32. North America Human Insulin Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Human Insulin Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Human Insulin Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Human Insulin Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Human Insulin Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Human Insulin Sales Value (2021-2032) & (US$ Million) Figure 38. South America Human Insulin Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Human Insulin Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Human Insulin Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Human Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Human Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Human Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Human Insulin Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Human Insulin Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Insulin Analogs and Biosimilars
  • Human Insulin Biologics
Applications
  • Short Acting
  • Pre-Mix Insulin
  • Long Acting
  • Intermediate Acting
Companies covered
  • Sanofi
  • ELI Lilly
  • B. Braun
  • Ypsomed
  • Wockhardt
  • NOVO Nordisk
  • Julphar
  • Biodel
  • Biocon
  • Becton, Dickinson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Insulin Sales Value (2021-2032)
  4. 1.2.2 Global Human Insulin Sales Volume (2021-2032)
  5. 1.2.3 Global Human Insulin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human Insulin Market Dynamics
  1. 2.1 Human Insulin Industry Trends
  2. 2.2 Human Insulin Industry Drivers
  3. 2.3 Human Insulin Industry Opportunities and Challenges
  4. 2.4 Human Insulin Industry Restraints
3 Human Insulin Market by Company
  1. 3.1 Global Human Insulin Company Revenue Ranking in 2025
  2. 3.2 Global Human Insulin Revenue by Company (2021-2026)
  3. 3.3 Global Human Insulin Sales Volume by Company (2021-2026)
  4. 3.4 Global Human Insulin Average Price by Company (2021-2026)
  5. 3.5 Global Human Insulin Company Ranking (2024-2026)
  6. 3.6 Global Human Insulin Company Manufacturing Base and Headquarters
  7. 3.7 Global Human Insulin Company Product Type and Application
  8. 3.8 Global Human Insulin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human Insulin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human Insulin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human Insulin Market by Type
  1. 4.1 Human Insulin Type Introduction
  2. 4.1.1 Insulin Analogs and Biosimilars
  3. 4.1.2 Human Insulin Biologics
  4. 4.2 Global Human Insulin Sales Volume by Type
  5. 4.2.1 Global Human Insulin Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Human Insulin Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Human Insulin Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Human Insulin Sales Value by Type
  9. 4.3.1 Global Human Insulin Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Human Insulin Sales Value by Type (2021-2032)
  11. 4.3.3 Global Human Insulin Sales Value Share by Type (2021-2032)
5 Human Insulin Market by Application
  1. 5.1 Human Insulin Application Introduction
  2. 5.1.1 Short Acting
  3. 5.1.2 Pre-Mix Insulin
  4. 5.1.3 Long Acting
  5. 5.1.4 Intermediate Acting
  6. 5.2 Global Human Insulin Sales Volume by Application
  7. 5.2.1 Global Human Insulin Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Human Insulin Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Human Insulin Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Human Insulin Sales Value by Application
  11. 5.3.1 Global Human Insulin Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Human Insulin Sales Value by Application (2021-2032)
  13. 5.3.3 Global Human Insulin Sales Value Share by Application (2021-2032)
6 Human Insulin Regional Sales and Value Analysis
  1. 6.1 Global Human Insulin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Insulin Sales by Region (2021-2032)
  3. 6.2.1 Global Human Insulin Sales by Region: 2021-2026
  4. 6.2.2 Global Human Insulin Sales by Region (2027-2032)
  5. 6.3 Global Human Insulin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human Insulin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human Insulin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human Insulin Sales Value by Region (2027-2032)
  9. 6.5 Global Human Insulin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human Insulin Sales Value (2021-2032)
  12. 6.6.2 North America Human Insulin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human Insulin Sales Value (2021-2032)
  15. 6.7.2 Europe Human Insulin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human Insulin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human Insulin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human Insulin Sales Value (2021-2032)
  21. 6.9.2 South America Human Insulin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human Insulin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human Insulin Sales Value Share by Country, 2025 VS 2032
7 Human Insulin Country-level Sales and Value Analysis
  1. 7.1 Global Human Insulin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Insulin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human Insulin Sales by Country (2021-2032)
  4. 7.3.1 Global Human Insulin Sales by Country (2021-2026)
  5. 7.3.2 Global Human Insulin Sales by Country (2027-2032)
  6. 7.4 Global Human Insulin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human Insulin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human Insulin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human Insulin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human Insulin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human Insulin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human Insulin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human Insulin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human Insulin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human Insulin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human Insulin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human Insulin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human Insulin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human Insulin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human Insulin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human Insulin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human Insulin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human Insulin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human Insulin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human Insulin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human Insulin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human Insulin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human Insulin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human Insulin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human Insulin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human Insulin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human Insulin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human Insulin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human Insulin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human Insulin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human Insulin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human Insulin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human Insulin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human Insulin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human Insulin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human Insulin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human Insulin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human Insulin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human Insulin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human Insulin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human Insulin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human Insulin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human Insulin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human Insulin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human Insulin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human Insulin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human Insulin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human Insulin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human Insulin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human Insulin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human Insulin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human Insulin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human Insulin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human Insulin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human Insulin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human Insulin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human Insulin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human Insulin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human Insulin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human Insulin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human Insulin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human Insulin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human Insulin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human Insulin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human Insulin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human Insulin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human Insulin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human Insulin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human Insulin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human Insulin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human Insulin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human Insulin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human Insulin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human Insulin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human Insulin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human Insulin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human Insulin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human Insulin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human Insulin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human Insulin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human Insulin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human Insulin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human Insulin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human Insulin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human Insulin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human Insulin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human Insulin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Human Insulin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Human Insulin Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 ELI Lilly
  8. 8.2.1 ELI Lilly Company Information
  9. 8.2.2 ELI Lilly Business Overview
  10. 8.2.3 ELI Lilly Human Insulin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 ELI Lilly Human Insulin Product Portfolio
  12. 8.2.5 ELI Lilly Recent Developments
  13. 8.3 B. Braun
  14. 8.3.1 B. Braun Company Information
  15. 8.3.2 B. Braun Business Overview
  16. 8.3.3 B. Braun Human Insulin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 B. Braun Human Insulin Product Portfolio
  18. 8.3.5 B. Braun Recent Developments
  19. 8.4 Ypsomed
  20. 8.4.1 Ypsomed Company Information
  21. 8.4.2 Ypsomed Business Overview
  22. 8.4.3 Ypsomed Human Insulin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Ypsomed Human Insulin Product Portfolio
  24. 8.4.5 Ypsomed Recent Developments
  25. 8.5 Wockhardt
  26. 8.5.1 Wockhardt Company Information
  27. 8.5.2 Wockhardt Business Overview
  28. 8.5.3 Wockhardt Human Insulin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Wockhardt Human Insulin Product Portfolio
  30. 8.5.5 Wockhardt Recent Developments
  31. 8.6 NOVO Nordisk
  32. 8.6.1 NOVO Nordisk Company Information
  33. 8.6.2 NOVO Nordisk Business Overview
  34. 8.6.3 NOVO Nordisk Human Insulin Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 NOVO Nordisk Human Insulin Product Portfolio
  36. 8.6.5 NOVO Nordisk Recent Developments
  37. 8.7 Julphar
  38. 8.7.1 Julphar Company Information
  39. 8.7.2 Julphar Business Overview
  40. 8.7.3 Julphar Human Insulin Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Julphar Human Insulin Product Portfolio
  42. 8.7.5 Julphar Recent Developments
  43. 8.8 Biodel
  44. 8.8.1 Biodel Company Information
  45. 8.8.2 Biodel Business Overview
  46. 8.8.3 Biodel Human Insulin Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Biodel Human Insulin Product Portfolio
  48. 8.8.5 Biodel Recent Developments
  49. 8.9 Biocon
  50. 8.9.1 Biocon Company Information
  51. 8.9.2 Biocon Business Overview
  52. 8.9.3 Biocon Human Insulin Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Biocon Human Insulin Product Portfolio
  54. 8.9.5 Biocon Recent Developments
  55. 8.10 Becton, Dickinson
  56. 8.10.1 Becton, Dickinson Company Information
  57. 8.10.2 Becton, Dickinson Business Overview
  58. 8.10.3 Becton, Dickinson Human Insulin Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Becton, Dickinson Human Insulin Product Portfolio
  60. 8.10.5 Becton, Dickinson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Insulin Value Chain Analysis
  2. 9.1.1 Human Insulin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Insulin Sales Mode & Process
  6. 9.2 Human Insulin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Insulin Distributors
  9. 9.2.3 Human Insulin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst